X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

FDA Comes With A Research Map Concerning Biosimilars Program

Content Team by Content Team
31st January 2023
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The FDA has gone on to release the Biosimilar User Fee Amendments III Regulatory Science Pilot Program, called the Research Roadmap, to give out more information on the biosimilar regulatory science research pilot program. The agency has gone on to open a public docket that collects feedback, as per a press release.

The regulatory science pilot programme helps in the development of effective and secure biosimilars as well as interchangeable biosimilars for patients by supporting the FDA’s review of biosimilar submissions. There will be a regulatory science programme that will be piloted by the FDA in order to facilitate interchangeable biological product development as well as biosimilars, as mentioned in the BsUFA reauthorization letter of commitment for fiscal years ranging from 2023 to 2027.

The regulatory research pilot programme pinpoints the knowledge gaps and directs research in order to facilitate biosimilar development. The regulatory research pilot programme has two goals, also known as demonstration projects- the first is advancing the interchangeable products development and the second is enhancing the efficiency of biosimilar product development.

On the roadmap, the research areas that are stressed here may impact science-based recommendation as well as regulatory decision making. To be more exact, the research aims at-

  • Increasing the capabilities as well as accuracy of analytical- both structural and functional as well as chemistry, manufacturing and also controls characterization.
  • Developing certain alternatives in order to reduce the study size that involves human subjects.

The research team, which happens to be both internal as well as external to the FDA must make use of this roadmap so as to guide research proposals, partnerships, and any other efforts as they look to have BsUFA III research funding opportunities. The roadmap also includes data on research project deliverable dates and the methods to consider when it comes to research conducted as per the pilot project.

Overall, the entire objective of the pilot programme is to make sure that the efficiency and predictability of biosimilar development are enhanced, which further helps in reducing both the cost and time for development. This would help in increasing the access and availability to the much-required biological treatment option for the patients.

Previous Post

Getting Immunotherapy Work In Case of Pancreatic Cancer

Next Post

The Top 3 Questions Looming Over Pharma Sector This 2023

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

The Top 3 Questions Looming Over Pharma Sector This 2023

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In